Company intelligence / Profile preview

ProCyte

Ownership: Private
Employees: ~1
Development stage: Other

Overview

ProCyte developed and commercialized copper peptide-based products for dermatological applications, including skin health, hair care, and wound healing. The company reported increasing revenues and cash-positive quarters in 2001 with a focus on achieving profitability by 2002. It also engaged in contract manufacturing for cGMP process development and small-scale production.

Therapeutic areas: Dermatology
Modalities: Small moleculeProtein
Industry: Biotech

Drug pipeline

1 asset

prezatide copper

Preclinical

Partnerships

Licensees for copper-peptide technology; specifics not publicly detailed

Beyond the preview

Go deeper on ProCyte.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProCyte.

Explore the full profile